Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer

详细信息    查看全文

• 作者：Hongying Lv (1)
  Qicai Li (1)
  Wengsheng Qiu (1)
  Jinyu Xiang (1)
  Hongjun Wei (2)
  Hua Liang (3)
  Aihua Sui (1)
  Jun Liang (1)
  
• 关键词：Colorectal neoplasms/genetics ; Polymorphism ; Oxaliplatin/drug therapy ; X ; ray repair cross complementing 1/genetics
• 刊名：Pathology & Oncology Research
• 出版年：2012
• 出版时间：October 2012
• 年：2012
• 卷：18
• 期：4
• 页码：1009-1014
• 全文大小：181KB
• 参考文献：1. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83(1):18-9. doi:10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M CrossRef
  2. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66(2):225-37 CrossRef
  3. Lentz F, Tran A, Rey E, Pons G, Treluyer JM (2005) Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics 5(1):21-3 CrossRef
  4. Kang D (2003) Genetic polymorphisms and cancer susceptibility of breast cancer in Korean women. J Biochem Mol Biol 36(1):28-4 CrossRef
  5. Friedberg EC (2001) How nucleotide excision repair protects against cancer. Nat Rev Cancer 1(1):22-3. doi:10.1038/35094000 CrossRef
  6. Tian M, Shinkura R, Shinkura N, Alt FW (2004) Growth retardation, early death, and DNA repair defects in mice deficient for the nucleotide excision repair enzyme XPF. Mol Cell Biol 24(3):1200-205 CrossRef
  7. Mort R, Mo L, McEwan C, Melton DW (2003) Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer 89(2):333-37. doi:10.1038/sj.bjc.6601061 CrossRef
  8. Motycka TA, Bessho T, Post SM, Sung P, Tomkinson AE (2004) Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52. J Biol Chem 279(14):13634-3639. doi:10.1074/jbc.M313779200 CrossRef
  9. Nagasubramanian R, Innocenti F, Ratain MJ (2003) Pharmacogenetics in cancer treatment. Annu Rev Med 54:437-52. doi:10.1146/annurev.med.54.101601.152352 CrossRef
  10. Chacko P, Rajan B, Joseph T, Mathew BS, Pillai MR (2005) Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res Treat 89(1):15-1. doi:10.1007/s10549-004-1004-x CrossRef
  11. Kiyohara C, Takayama K, Nakanishi Y (2006) Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 54(3):267-83. doi:10.1016/j.lungcan.2006.08.009 CrossRef
  12. Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW (2006) XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 15(12):2384-390. doi:10.1158/1055-9965.EPI-06-0381 CrossRef
  13. Zhang Z, Miao XP, Tan W, Guo YL, Zhang XM, Lin DX (2006) Correlation of genetic polymorphisms in DNA repair genes ADPRT and XRCC1 to risk of gastric cancer. Ai Zheng 25(1):7-0
  14. Kim DY, Kim YB, Choi HS, Kim JM, Suh K (2006) Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, MTHFR or XRCC1 gene? Ann Surg Oncol 13(2):7-
  15. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, Lenz HJ (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21(4B):3075-079
  16. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L (2007) Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15(10):1049-053. doi:10.1038/sj.ejhg.5201884 CrossRef
  17. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22(13):2594-601. doi:10.1200/JCO.2004.08.067JCO.2004.08.067 CrossRef
  
• 作者单位：Hongying Lv (1)
  Qicai Li (1)
  Wengsheng Qiu (1)
  Jinyu Xiang (1)
  Hongjun Wei (2)
  Hua Liang (3)
  Aihua Sui (1)
  Jun Liang (1)
  
  1. The Affiliated Hospital of Qingdao University Medical College, CN-Qingdao, 266003, People’s Republic of China
  2. Department of Pathology, Qingdao Municipal Hospital, Qingdao, 266027, People’s Republic of China
  3. Department of Oncology, Qingdao Oncology Hospital, Qingdao, 266074, People’s Republic of China
  
• ISSN：1532-2807

文摘

To examine the association between genetic polymorphisms of XRCC1 Arg399Gln(G→A) and response to oxaliplatin-based chemotherapy in advanced colorectal cancer. XRCC1 genotypes of totally 99 patients(37 stage III, 62 stage IV)with advanced colorectal cancer treated with oxaliplatin-based chemotherapy were detected by TaqMan-MGB probe allelic discrimination method. And clinical response of 62 patients in stage IVafter 2 to 3 cycles of chemotherapy were evaluated. Also time to progress (TTP) of all patients were evaluated. Of the genotype frequencies in all patients, up to 52.53?% were G/G genotype, 9.09?% were A/A genotype, and 38.38?% were G/A genotype. The response rate (CR+PR) of 62 patients in stage IV was 61.29?% (19/31). Patients with G/G genotype showed enhanced respond to chemotherapy compared to those with G/A+A/A (x 2--.6, P--.029; OR--.845, 95?%CI--.231?~-2.01, P--.018). Individuals with the G/G genotype had a TTP of 10.0 (8.88-1.12) months, those with the G/A+A/A genotype had an TTP of 5.0(4.26-.74) months. The log-rank test was marginally significant (x 2--9.20, P-lt;-.01). The Cox proportional hazards model, adjusted for stage, performance status, and chemotherapy regimen, showed that only XRCC1 G/G genotypes increases the OR significantly (OR--.555; 95?% CI, 2.119?~-.963; P-lt;-.01). The results suggest that XRCC1 Arg399Gln polymorphisms is associated with the response to oxaliplantin-based chemotherapy and time to progression in advanced colorectal cancer in Chinese population. It is proposed that the XRCC1 Arg399Gln polymorphism should be routinely detected to screen patients who are more likely benefit from oxaliplantin-based treatment.